dr. alan p. venook on determining frontline treatment for mcrc
Published 7 years ago • 90 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:47
alan venook, md relays the optimal dose for regorafenib (stivarga) in the 2nd line treatment of mcrc
-
1:12
dr. atreya on how the nccn guidelines have impacted treatment options in mcrc
-
1:54
alan p. venook, md, on integrating immunotherapy into existing treatment regimens for hcc patients
-
1:03
dr. venook on looking ahead at treatment for crc
-
10:24
alan p. venook, et al.
-
1:13
alan venook, md, on the impact of dose escalation of regorafenib in mcrc patients
-
58:56
genomics england research seminar july 2023 - early career researchers cancer showcase
-
40:04
is immunotherapy an option for colorectal cancer patients? with dr. dung le
-
13:00
biomarkers for cancer on the pancreas
-
2:56
treatment options for colorectal cancer
-
1:26
dr. alan venook on geographic variations in the therapies used to treat cancer
-
6:24
interview dr. alan p. venook, wcgic 2014
-
10:06
understanding tumor sidedness in colorectal cancer
-
10:00
imugene begins vaxinia trial for bile tract cancer
-
1:37
alan p. venook, md, on integrating immunotherapy into existing treatment regimens for crc patients
-
0:50
dr. venook: what are your choices for fourth-line treatment in this patient?
-
1:00:22
allycon 2021: how to navigate clinical trials for colorectal cancer
-
1:39
alan venook, md, discusses next generation sequencing and mcrc treatment
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
1:23
dr. venook on immunotherapy potential in colorectal cancer
-
1:30
alan venook, md, discusses vemurafenib and the nccn guidelines for mcrc patients
-
1:05
alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients